Immunotherapy plus chemotherapy before surgery for limited-stage esophageal small cell carcinoma
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs — one immunotherapy (serplulimab) plus two chemotherapies (etoposide and cisplatin) — given before surgery to shrink esophageal cancer and improve outcomes. It is for patients with limited-stage small cell carcinoma of the esophagus that has not spread far.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be diagnosed as small cell carcinoma of the esophagus — a rare type of esophageal cancer.
- The cancer must be limited to the esophagus and nearby lymph nodes, without spreading to distant organs.
- You should be generally active and able to take care of yourself (ECOG 0 or 1).
- You must not have had prior immunotherapy or have an active autoimmune disease.
- Your blood counts, kidney, and liver function need to be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and radiation for esophageal small cell carcinoma. The goal is to see if this combination improves outcomes for patients who have not been treated before.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can shrink esophageal cancer and improve outcomes. It is designed for patients with early-stage but treatable esophageal squamous cell carcinoma who are candidates for surgery.
This study is testing a new combination treatment for early-stage small-cell lung cancer. It compares giving immunotherapy drugs (PD-1/PD-L1 inhibitors) along with chemotherapy before surgery versus chemotherapy alone, to see if the combination helps shrink tumors more effectively and improves outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
Hear when a new Small-Cell Carcinoma of the Esophageal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.